公开(公告)号：US20180105527A1

公开(公告)日：2018-04-19

申请号：US15567692

申请日：2016-06-01

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Ge Hyeong Lee ,  Hee-Jong Lim ,  Heeyeong Cho ,  Woo Kyu Park ,  Seong Hwan Kim ,  Jung Hwan Choi

IPC: C07D487/04 ,  C07D471/04

Abstract: The present invention relates to a heteroaryl derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition for preventing or treating diseases associated with PI3 kinases, containing the same as an active ingredient. The heteroaryl derivative according to the present invention has an excellent effect of selectively inhibiting PI3 kinases, thereby being useful in preventing or treating PI3 kinase diseases such as: cancers, autoimmune diseases, and respiratory diseases.

公开(公告)号：US11767297B2

公开(公告)日：2023-09-26

申请号：US17939147

申请日：2022-09-07

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

Inventor： Sung Youn Chang ,  Hyuk Lee ,  Ki Young Kim ,  Bum Tae Kim ,  Sung Soo Kim ,  Seong Hwan Kim ,  Hwan Jung Lim ,  Jung Nyoung Heo ,  Sang Joon Shin ,  Sang Youn Park

IPC: A61K31/4745 ,  C07D231/38 ,  A61P35/04 ,  C07D401/04 ,  C07D401/14 ,  C07D403/10 ,  C07D409/04 ,  C07D417/04

CPC classification number: C07D231/38 ,  A61P35/04 ,  C07D401/04 ,  C07D401/14 ,  C07D403/10 ,  C07D409/04 ,  C07D417/04 ,  A61K31/4745 ,  A61K31/4745 ,  A61K2300/00 ,  A61K31/4155 ,  A61K2300/00 ,  A61K31/415 ,  A61K2300/00 ,  A61K31/4439 ,  A61K2300/00 ,  A61K31/427 ,  A61K2300/00 ,  A61K31/496 ,  A61K2300/00 ,  A61K31/5377 ,  A61K2300/00 ,  A61K31/454 ,  A61K2300/00

Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.

公开(公告)号：US11485711B2

公开(公告)日：2022-11-01

申请号：US16967844

申请日：2019-01-31

Applicant: Korea Research Institute of Chemical Technology ,  Industry-Academic Cooperation Foundation, Yonsei University

Inventor： Sung Youn Chang ,  Hyuk Lee ,  Ki Young Kim ,  Bum Tae Kim ,  Sung Soo Kim ,  Seong Hwan Kim ,  Hwan Jung Lim ,  Jung Nyoung Heo ,  Sang Joon Shin ,  Sang Youn Park

IPC: C07D231/38 ,  A61P35/04 ,  C07D401/04 ,  C07D401/14 ,  C07D403/10 ,  C07D409/04 ,  C07D417/04 ,  A61K31/4745

Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.

公开(公告)号：US11447469B2

公开(公告)日：2022-09-20

申请号：US16967825

申请日：2019-01-31

Applicant: Korea Research Institute of Chemical Technology ,  Industry-Academic Cooperation Foundation, Yonsei University

Inventor： Sung Youn Chang ,  Hyuk Lee ,  Ki Young Kim ,  Bum Tae Kim ,  Sung Soo Kim ,  Seong Hwan Kim ,  Hwan Jung Lim ,  Jung Nyoung Heo ,  Sang Joon Shin ,  Sang Youn Park

IPC: C07D403/12 ,  C07D401/12 ,  C07D403/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14

Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.

公开(公告)号：US10526337B2

公开(公告)日：2020-01-07

申请号：US15567692

申请日：2016-06-01

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Ge Hyeong Lee ,  Hee-Jong Lim ,  Heeyeong Cho ,  Woo Kyu Park ,  Seong Hwan Kim ,  Jung Hwan Choi

IPC: C07D487/04 ,  A61K31/506 ,  C07D471/04

Abstract: The present invention relates to a heteroaryl derivative represented by Formula 1 wherein , A, R1, R2, R3, R4, and R5 are as defined herein, or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition for preventing or treating diseases associated with PI3 kinases, containing the same as an active ingredient. The heteroaryl derivative according to the present invention has an excellent effect of selectively inhibiting PI3 kinases, thereby being useful in preventing or treating PI3 kinase diseases such as cancers, autoimmune diseases, and respiratory diseases.